Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 9,143 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm, Fallopian Tube Transitional Cell Carcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine; Other · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Leukemia
Interventions: filgrastim, cladribine, cytarabine, etoposide, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 35
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 27 more

Conditions: Stenoses, Carotid
Interventions: Carotid Endarterectomy, FDA-approved carotid stents, Intensive Medical Management; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years and older
Enrollment: 2,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: CD33 Positive Acute Myelogenous Leukemia
Interventions: Antibody Drug Conjugate Chemotherapeutic; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 142
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 64 more

Conditions: Epilepsy, Dravet Syndrome
Interventions: GWP42003-P 20 mg/kg/day Dose, Placebo control; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 13
States / cities: Miami, Florida • Orlando, Florida • Atlanta, Georgia + 10 more

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: sorafenib tosylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heart Failure
Interventions: Stepped pharmacologic care, Ultrafiltration; Drug · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Atlanta, Georgia • Minneapolis, Minnesota + 5 more

Conditions: Gastroesophageal Reflux
Interventions: Magnetic Sphincter Augmentation; Device
Lead sponsor: Torax Medical Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • Jacksonville, Florida + 10 more

Conditions: Granulin Mutation
Interventions: FRM-0334, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 5
States / cities: San Francisco, California • Orlando, Florida • Boston, Massachusetts + 2 more

Conditions: Large B-cell Lymphoma, Follicular Lymphoma
Interventions: Axicabtagene Ciloleucel; Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
U.S. locations: 52
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more

Conditions: B-cell Malignancies
Interventions: Zanubrutinib; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 4
States / cities: Gilbert, Arizona • Ann Arbor, Michigan • Rochester, Minnesota + 1 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414; Drug · Radiation
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 68
States / cities: Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Docetaxel, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 16
States / cities: Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 13 more

Conditions: Kidney Cancer
Interventions: fenretinide; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 4
States / cities: Detroit, Michigan • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more

Conditions: Thyroid Carcinoma, Anaplastic
Interventions: Lenvatinib 24 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 14
States / cities: Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 9 more

Conditions: Long COVID
Interventions: Fermented foods, Control; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Distal Femur Fracture
Interventions: Single distal femur implant, Dual distal femur implants; Procedure
Lead sponsor: University of Utah; Other
Eligibility: 60 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Rochester, Minnesota • New York, New York • Portland, Oregon + 2 more

Conditions: Atrial Fibrillation
Interventions: Patient Decision Aid, Encounter Decision Aid; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 1,117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • Ann Arbor, Michigan + 3 more

Conditions: Obesity
Interventions: Telemedicine 30-day post-op visit, In-Person 30-day post-op visit; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Electronic Health Record Review, Interview, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: University of Rochester NCORP Research Base; Other
Eligibility: 18 Years and older
Enrollment: 2,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 259
States / cities: Jonesboro, Arkansas • Anaheim, California • Antioch, California + 203 more

Conditions: Pain, Postoperative
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions: MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Leucovorin Calcium, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 30 Years to 70 Years
Enrollment: 488 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 531
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more

Conditions: Heart Failure
Interventions: Inspiratory Muscle Training; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

CREST-2 Long-term Observational Extension Study

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)

LINX Reflux Management System Clinical Study Protocol

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Chemotherapy in Treating Patients With Advanced Kidney Cancer

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Evaluating the Effects of a Fermented Diet on Microbiome Diversity in Individuals With Long COVID

Dual Implant Versus Single Implant Distal End of Femur

Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation

Telemedicine Follow-up for Bariatric Surgery Patients: What Do Patients Prefer

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

Ultrasound Image Quality of the Brachial Plexus at the Interscalene Space Before and After Shoulder Arthroscopy

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Inspiratory Muscle Training in HFpEF